Recently, Kim H et al reported that downregulation of RNF125 underlay resistance of melanoma cells to BRAF inhibitors via JAK1 deregulation, suggesting that combination therapies targeting both JAK1 and EGFR could be effective against BRAFi-resistant tumors with de novo low RNF125 expression [19]. The gene discussed is JAK1; the disease is melanoma.